Evidence map›Paper›PMID 39913351›Full record

ArticlePloS one2025

Nutraceutical COMP-4 confers protection against endothelial dysfunction through the eNOS/iNOS-NO-cGMP pathway.

Monica G Ferrini, Andrea Abraham, Revecca Millán, Leslie Graciano, Sriram V Eleswarapu, Jacob Rajfer

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Monica G FerriniDepartment of Health and Life Sciences, Charles R. Drew University of Medicine and Science, Los Angeles, California, United States of America.
Andrea AbrahamDepartment of Health and Life Sciences, Charles R. Drew University of Medicine and Science, Los Angeles, California, United States of America.
Revecca MillánDepartment of Health and Life Sciences, Charles R. Drew University of Medicine and Science, Los Angeles, California, United States of America.ORCID 0000-0002-0089-5372
Leslie GracianoDepartment of Health and Life Sciences, Charles R. Drew University of Medicine and Science, Los Angeles, California, United States of America.
Sriram V EleswarapuDepartment of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America.ORCID 0000-0003-1852-4833
Jacob RajferDepartment of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America.

Funding

Workshop for Junior Biostatisticians in Health ResearchU54MD007598 · NIMHD · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI Ali Andalibi, Jose A Torres-Ruiz · 2012 to 2026
$60.0M
NIMHD NIH HHS U54 MD007598
6 · The paper itself

Abstract

The nutraceutical COMP-4 -consisting of L-citrulline, ginger extract, and herbal components Paullinia cupana and muira puama-has been shown previously to stimulate the production of nitric oxide (NO) in a variety of tissue types. We hypothesized that COMP-4 may have a protective, stimulatory effect on the vascular endothelial cell. Human umbilical arterial endothelial cells were incubated for 24 hours with or without COMP-4 and, to replicate impairment of endothelial function, co-incubated with or without H2O2. NO intracellular content, nitrite formation and cGMP content in culture media, nitric oxide synthase (NOS) isoforms and mRNA content, pro-inflammatory cytokines, and PAI-1 expression and activity were measured. COMP-4 increased endothelial cell production of NO and cGMP and the expression of both endothelial NOS (eNOS) and inducible NOS (iNOS), in tandem with a reduction in cytokine expression and activity of PAI-1. Co-incubation of COMP-4 with H2O2 reversed detrimental effects of H2O2 on endothelial function, evidenced by improvement in NO availability and abrogation of the pro-inflammatory milieu. These results suggest that COMP-4 exerts a stimulatory effect on endothelial cell eNOS and iNOS to increase NO bioavailability, leading to a reduction in pro-inflammatory cytokines, particularly the prothrombotic PAI-1.

Indexed as

CitrullineCyclic GMPDietary SupplementsEndothelial CellsEndothelium, VascularNitric OxideNitric Oxide Synthase Type IINitric Oxide Synthase Type IIISignal TransductionCytokinesHumansHuman Umbilical Vein Endothelial CellsHydrogen PeroxidePlasminogen Activator Inhibitor 1CitrullineCyclic GMPCytokinesHydrogen PeroxideNitric OxideNitric Oxide Synthase Type IINitric Oxide Synthase Type IIINOS2 protein, humanNOS3 protein, humanPlasminogen Activator Inhibitor 1

Identifiers

PMID39913351
PMCPMC11801596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.